Engineering IL-12 for tumor specific cytotoxicity results in enhanced therapeutic window

Time: 2:30 pm

Details:

• Multiple attenuating components help to mask IL-12 off-tumor mediated cytotoxicity
• Tumor specific activation of IL12-Fc elicits a potent anti-tumor activity in xenograft models
• No dose limiting toxicity observed in cynomolgus monkeys at levels well above expected therapeutic doses